1. Home
  2. RILY vs CUVL Comparison

RILY vs CUVL Comparison

Compare RILY & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RILY

B. Riley Financial Inc.

N/A

Current Price

$6.79

Market Cap

349.8M

Sector

Finance

ML Signal

N/A

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

N/A

Current Price

$5.93

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
RILY
CUVL
Founded
1973
N/A
Country
United States
Australia
Employees
N/A
16
Industry
Investment Managers
Miscellaneous
Sector
Finance
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
349.8M
374.2M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
RILY
CUVL
Price
$6.79
$5.93
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
468.6K
19.7K
Earning Date
03-31-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
138.49
N/A
EPS
6.47
N/A
Revenue
$967,599,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.09
N/A
Revenue Growth
15.38
N/A
52 Week Low
$3.64
$5.95
52 Week High
$11.24
$8.20

Technical Indicators

Market Signals
Indicator
RILY
CUVL
Relative Strength Index (RSI) 43.44 37.95
Support Level $6.45 N/A
Resistance Level $7.83 $7.04
Average True Range (ATR) 0.24 0.45
MACD 0.00 -0.10
Stochastic Oscillator 35.81 1.30

Price Performance

Historical Comparison
RILY
CUVL

About RILY B. Riley Financial Inc.

BRC Group Holdings Inc is a diversified holding company offering a platform of businesses, including financial services (with complementary banking and wealth management businesses), telecom, retail, and investments in equity, debt, and venture capital. It serves retail, corporate, capital providers, and individual customers across different business lines. The Group reports its activities in seven reportable business segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, UOL, and Consumer Products. Maximum revenue is generated from the Consumer Products segment, which offers mobile computing accessories and home furnishing products. Geographically, the Group derives its revenue from North America.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: